Conduit Pharmaceuticals Files 8-K: Agreements, Obligations, and Equity Sales
Ticker: CDTTW · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $11.50, $5,737,500, $0.10, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Conduit Pharma inked a deal, took on debt, and sold stock on Nov 22. Big moves!
AI Summary
Conduit Pharmaceuticals Inc. entered into a material definitive agreement on November 22, 2024. The company also incurred a direct financial obligation or an obligation under an off-balance sheet arrangement. Additionally, Conduit Pharmaceuticals Inc. reported unregistered sales of equity securities and filed financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions by Conduit Pharmaceuticals, including new financial commitments and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, suggesting potential financial risks or strategic shifts for the company.
Key Numbers
- 0.0001 — Par Value Per Share (Common Stock)
- 11.50 — Exercise Price (Redeemable Warrants)
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- November 22, 2024 (date) — Date of earliest event reported
- 0.0001 (dollar_amount) — Par value per share of Common Stock
- 11.50 (dollar_amount) — Exercise price for Redeemable Warrants
FAQ
What is the nature of the material definitive agreement entered into by Conduit Pharmaceuticals Inc. on November 22, 2024?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of direct financial obligation or off-balance sheet arrangement did Conduit Pharmaceuticals Inc. enter into?
The filing states that Conduit Pharmaceuticals Inc. created a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed in the provided text.
When were the unregistered sales of equity securities by Conduit Pharmaceuticals Inc. made?
The filing indicates unregistered sales of equity securities occurred, with the earliest event reported on November 22, 2024.
What is the par value per share of Conduit Pharmaceuticals Inc.'s common stock?
The par value per share of Conduit Pharmaceuticals Inc.'s common stock is $0.0001.
What is the exercise price for the redeemable warrants issued by Conduit Pharmaceuticals Inc.?
The exercise price for the redeemable warrants is $11.50 per share.
Filing Stats: 1,509 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-11-25 16:53:37
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $5,737,500 — tible Note") in the principal amount of $5,737,500 to evidence the Holder's currently owed
- $0.10 — he "Common Stock"), at a fixed price of $0.10 (or following any reverse splits that m
- $1.00 — version date, but in no event less than $1.00), subject to adjustment as provided the
- $2,650,000 — d") in the original principal amount of $2,650,000, inclusive of a $500,000 original issua
- $500,000 — al amount of $2,650,000, inclusive of a $500,000 original issuance discount. In October
- $100,000 — e obligated to pay Nirland a penalty of $100,000 per day until the special meeting is he
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex4-1.htm (EX-4.1) — 107KB
- ex4-2.htm (EX-4.2) — 19KB
- 0001493152-24-047631.txt ( ) — 429KB
- cdt-20241122.xsd (EX-101.SCH) — 4KB
- cdt-20241122_def.xml (EX-101.DEF) — 29KB
- cdt-20241122_lab.xml (EX-101.LAB) — 36KB
- cdt-20241122_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 25, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer